Skip to main content

Mass General to Use Helicos Sequencer for Cancer Research


This article was originally published Aug. 13.

Helicos BioSciences said last week that it has placed a Helicos Genetic Analysis System at the Massachusetts General Hospital Cancer Center.

The instrument has been installed in the lab of Daniel Haber, who will explore the use of the system for use in characterizing circulating tumor cells, the company said.

Helicos did not disclose the financial terms of the agreement.

Patrice Milos, CSO of Helicos, said in a statement that the company expects "great synergies" for cancer research and diagnostics through the combination MGH's circulating tumor cell microchip and the Helicos system.

The placement follows the company's announcement earlier this month that it had sold one of its sequencers to an undisclosed biotechnology company in the Northeast (see In Sequence Aug. 4, 2009), and the publication last week of the first human genome to be sequenced on the system (see story, this issue).

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.